In our latest Liberty Update, CFIF highlights the debut of the "Most Favored Patient" initiative, which offers the optimal blueprint going forward for lower drug costs, greater access and better healthcare.

Well, the policy heavyweights behind Most Favored Patient come from the group at Unleash Prosperity, including Steve Forbes, Stephen Moore, Phil Kerpen, and Thomas Philipson.  And in addition to their new work at Most Favored Patient, they've unveiled a new commentary explaining how drug prices in the U.S. are actually cheaper than in other developed nations with which we're often unfairly compared:

It IS true that Americans pay more for new drugs under patent. That, of course, is because American pharmaceutical companies spend billions of dollars inventing the major breakthrough…[more]